Innate Pharma SA (IPHA) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Outcome of Innate Pharma’s 2024 Annual General Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its...

Innate Pharma: Clarification concernant le statut de SAR443579

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui qu’un abstract...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHA

Deux abstracts concernant SAR443579 (IPH6101), le candidat-médicament le plus avancé de la plateforme ANKET®, un NK Cell Engager trifonctionnel...

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024...

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a...

L’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce la tenue de son Assemblée...